AMBS Amarantus Bioscience Holdings Inc (CE)

EDISON EQUITY RESEARCH:  AMARANTUS BIOSCIENCE - BUILDING UP THERAPEUTICS ASSETS

Amarantus has acquired several pre-commercial therapeutic assets in recent years, and intends to create value by furthering their development before out-licensing or commercialising them. The firm recently acquired ESS-W, which can shorten the time needed to treat severe burns. Eltoprazine aims to reduce involuntary movements associated with long-term levodopa therapy in Parkinson’s disease. These candidates provide long-term potential, and drive our $76m rNPV.

Amarantus BioScience is a San Francisco-based life sciences firm developing therapeutics in multiple indications. Eltoprazine is in Phase IIb trials for Parkinson’s disease, levodopa-induced dyskinesia (PD-LID). The company’ Diagnostics subsidiary targets unmet need in neurology. 


To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports